Department of Neurology and Stroke Unit, San Camillo de' Lellis General Hospital, Rieti, Italy.
Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom.
Front Immunol. 2018 Sep 11;9:1921. doi: 10.3389/fimmu.2018.01921. eCollection 2018.
C-reactive protein (CRP) is an important mediator and a hallmark of the acute-phase response to inflammation. High-sensitivity assays that accurately measure levels of CRP have been recommended for use in risk assessment in ischemic stroke patients. Elevation of CRP during the acute-phase response in intracerebral hemorrhage (ICH) is also associated with the outcomes such as death and vascular complications. However, no association has been found with the increased risk of ICH. The aim of this review is to synthesize the published literature on the associations of CRP with acute ICH both as a risk biomarker and predictor of short- and long-term outcomes as well as its role as a pathogenic determinant. We believe before any clinical utility, a critical appraisal of the strengths and deficiencies of the accumulated evidence is required both to evaluate the current state of knowledge and to improve the design of future clinical studies.
C-反应蛋白（CRP）是炎症急性期反应的重要介质和标志。高灵敏度的检测方法可以准确测量 CRP 水平，已被推荐用于缺血性脑卒中患者的风险评估。脑出血（ICH）急性期反应中 CRP 的升高也与死亡和血管并发症等结局相关。然而，尚未发现与 ICH 风险增加相关。本综述的目的是综合已发表的关于 CRP 与急性 ICH 的关系的文献，包括作为风险生物标志物和短期及长期结局的预测因子，以及其作为致病性决定因素的作用。我们认为，在任何临床应用之前，都需要对已积累证据的优势和缺陷进行批判性评估，以评估当前的知识状态，并改进未来临床研究的设计。
